Search research articles
Contact Us
Filters
Showing results (151-160 of 536) with videos related to
Page
of 54
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2006
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide
Owen A O'Connor, Emily A Smith, Lorraine E Toner, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 29, 2007
Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells
Shujun Liu, Rebecca B Klisovic, Tamara Vukosavljevic, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 11, 2008
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation
Mehdi Hamadani, Craig C Hofmeister, Buffy Jansak, et al.
Leukemia & Lymphoma
|
January 2, 2024
Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib
Dat Ngo, Jose Tinajero, Shanpeng Li, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 12, 2022
MicroRNA networks in FLT3-ITD acute myeloid leukemia
Dinh Hoa Hoang, Dandan Zhao, Sergio Branciamore, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 30, 2008
Curcumin is a potent DNA hypomethylation agent
Zhongfa Liu, Zhiliang Xie, William Jones, et al.
Leukemia & Lymphoma
|
February 20, 2016
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665
Rebecca DeBoer, Gregory Koval, Flora Mulkey, et al.
Analytical Biochemistry
|
February 9, 2007
Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry
Xiaodan Su, Liwen Zhang, David M Lucas, et al.
Leukemia & Lymphoma
|
January 20, 2016
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia
Alison R Walker, Hongyan Wang, Katherine Walsh, et al.
Oncotarget
|
June 17, 2025
Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience
Fei Fei, Milhan Telatar, Vanina Tomasian, et al.
Page
of 54
Search research articles
Search
Showing results (151-160 of 536) with videos related to
Sort By:
Page
of 54
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2006
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide
Owen A O'Connor, Emily A Smith, Lorraine E Toner, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 29, 2007
Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells
Shujun Liu, Rebecca B Klisovic, Tamara Vukosavljevic, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 11, 2008
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation
Mehdi Hamadani, Craig C Hofmeister, Buffy Jansak, et al.
Leukemia & Lymphoma
|
January 2, 2024
Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib
Dat Ngo, Jose Tinajero, Shanpeng Li, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 12, 2022
MicroRNA networks in FLT3-ITD acute myeloid leukemia
Dinh Hoa Hoang, Dandan Zhao, Sergio Branciamore, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 30, 2008
Curcumin is a potent DNA hypomethylation agent
Zhongfa Liu, Zhiliang Xie, William Jones, et al.
Leukemia & Lymphoma
|
February 20, 2016
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665
Rebecca DeBoer, Gregory Koval, Flora Mulkey, et al.
Analytical Biochemistry
|
February 9, 2007
Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry
Xiaodan Su, Liwen Zhang, David M Lucas, et al.
Leukemia & Lymphoma
|
January 20, 2016
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia
Alison R Walker, Hongyan Wang, Katherine Walsh, et al.
Oncotarget
|
June 17, 2025
Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience
Fei Fei, Milhan Telatar, Vanina Tomasian, et al.
Page
of 54